Hims & Hers Health, Inc. (HIMS)
Pre-market:
| Previous close | 14.57 |
| Open | 15.95 |
| Bid | 19.22 x 1100 |
| Ask | 0.00 x 1300 |
| Day's range | 15.85 - 20.11 |
| 52-week range | 5.65 - 20.11 |
| Volume | |
| Avg. volume | 7,796,058 |
| Market cap | 3.995B |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
SAN FRANCISCO, May 20, 2024--Hims & Hers Health, Inc., the leading health and wellness platform, today announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving customers an affordable way to consistently access safe, high-quality weight loss treatment.
- Business Wire
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
SAN FRANCISCO, May 16, 2024--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company’s Board of Directors. Ms. Manuel is a co-founder and principal in Rice, Hadley, Gates & Manuel LLC, a strategic consulting firm founded in 2009 that helps U.S. companies navigate international markets and regulatory issues, and a former U.S. government official.
- Business Wire
Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results
SAN FRANCISCO, May 06, 2024--Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2024 in a shareholder letter that is posted at investors.hims.com.
